Sestak, Ivana http://orcid.org/0000-0001-6999-2851
Blake, Glen
Patel, Raj
Cuzick, Jack
Howell, Anthony
Coleman, Robert
Eastell, Richard
Funding for this research was provided by:
AstraZeneca (NA)
Cancer Research UK (C569/A5032)
Article History
Received: 17 June 2020
Revised: 1 December 2020
Accepted: 10 December 2020
First Online: 22 January 2021
Ethics approval and consent to participate
: The trial was approved by the UK North West Multicentre Research Ethics Committee and was done in accordance with the Declaration of Helsinki, under the principles of good clinical practice. Participants provided written informed consent.
: Data will be available according to IBIS-II’s data-sharing plan. Request for specific analyses or data can be submitted via email to j.cuzick@qmul.ac.uk. Details for data-sharing policy and application process can be found at ExternalRef removed.
: J.C. reports grants from AstraZeneca during the conduct of the study. J.C. is a member of the Editorial Board of the British Journal of Cancer. All other authors have no conflict of interest to declare.
: This study was funded by Cancer Research UK (C569/A5032), the National Health and Medical Research Council Australia (GNT300755, GNT569213), Manchester NIHR Biomedical Research Centre (IS-BRC-1215–20007), Sanofi Aventis, and AstraZeneca. AstraZeneca provided anastrozole and matching placebo. The study sponsor was Queen Mary University of London.